Patient Access to Lab Services

Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more…

Coinsurance would disrupt the ability of health care practitioners to work with their patients to ascertain the best lab tests to help best diagnose new conditions, manage existing conditions, and guide therapy, which is critical for the Medicare population as they often have multiple comorbidities. Currently, since there is no cost-sharing, patients who need more lab tests due to more complicated health conditions have no greater financial risk than patients those with less complex conditions when receiving their lab results – and a patient may not know whether their condition is simple or complex when they first see a doctor. Despite this common-sense approach, some policy-makers calling for entitlement reform and deficit reduction have proposed putting into place a new 20% patient coinsurance for clinical laboratory services as an attempt to make Medicare beneficiaries more aware of health care costs. In real life, coinsurance for lab services will dis-incentivize Medicare beneficiaries from receiving timely and life-saving clinical lab tests, thus increasing health care costs through worse outcomes, and would drastically increase the cost of providing lab services through generating millions of new patient bills.

Read More

  • Letter to Senators Reid and McConnell Regarding Coinsurance

    July 07, 2011
      The Honorable Harry Reid Majority Leader U.S. Senate 522 Hart Senate Office Building Washington, DC 20510 The Honorable Mitch McConnell Minority Leader U.S. Senate 317 Russell Senate Office Building Washington, DC 20510 Dear Majority Leader Reid and Minority Leader McConnell: The undersigned laboratory and health care organizations, representing America’s community, regional, and national laboratories, their employees, practitioners, and the Medicare patients we serveContinue Reading »...
  • Letter to Representative Don Young Regarding Coinsurance

    June 27, 2011
      June 27, 2011 The Honorable Don Young United States House of Representatives 2314 Rayburn House Office Building Washington, DC 20515 Dear Representative Young: The American Clinical Laboratory Association (ACLA) represents the leading providers of laboratory services in the United States. We are writing to convey our serious concerns about the possible imposition of coinsurance for clinical laboratory services provided under Medicare, as partContinue Reading »...
  • ACLA Supports Physician Guidance in Patient-Centered Genetic Testing

    May 12, 2010
    Washington DC – Consumers should seek the guidance of a personal physician or other health care provider in the use of direct to consumer genetic tests to ensure proper understanding of the results and appropriate follow-up, said the American Clinical Laboratory Association (ACLA) today. Recent media reports of genetic tests being marketed and sold directly to consumers in drug stores and other retail establishmentsContinue Reading »...
1 2 3 4